Form 4: Seres Therapeutics Executive Sells Shares to Cover Taxes After RSU Vesting

Lisa von Moltke, Executive Vice President and Chief Medical Officer at Seres Therapeutics, sold 977 shares of common stock to cover taxes related to the vesting of restricted stock units.

Summary

• Lisa von Moltke, an executive at Seres Therapeutics, sold 977 shares of common stock at an average price of $0.5407 per share.
• This sale was executed on November 18, 2024, and was part of a pre-arranged trading plan under Rule 10b5-1.
• The sale was intended to cover taxes associated with the vesting of 2,969 restricted stock units (RSUs) on November 15, 2024.
• The RSUs vest over time, with 25% vesting on February 15, 2024, and the remainder vesting in 12 equal quarterly installments.
• Following these transactions, Ms. von Moltke directly owns 32,415 shares of common stock and 26,719 restricted stock units.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any significant positive or negative sentiment.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, although this sale was for tax purposes and under a pre-arranged plan.
• The stock price could be sensitive to further sales by insiders.

Future Outlook

The remaining restricted stock units will continue to vest in 12 equal quarterly installments.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Industry Context

This type of transaction is common for executives who receive stock-based compensation. It is a routine part of executive compensation and is not unusual in the biotech industry.

Comparison to Industry Standards

• Many biotech companies use restricted stock units as part of their executive compensation packages.
• Rule 10b5-1 trading plans are a standard practice to allow insiders to sell shares without concerns about insider trading violations.
• The vesting schedule of the RSUs is typical for executive compensation packages.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but this is a routine transaction for tax purposes.

Key Dates

Keywords

Seres Therapeutics, insider trading, stock sale, restricted stock units, Rule 10b5-1, executive compensation, MCRB